RTP Mobile Logo
Oncology Grand Rounds: Investigators Discuss New Agents and Novel Therapies
Released December 2017

A special audio supplement to a CNE symposia series held during the 2017 ONS Annual Congress featuring expert comments on the application of emerging research to patient care. (Audio Content)

CE Disclosures and Faculty Information

    The treatment of solid tumors and hematologic cancers remains a challenge for many healthcare professionals. The advent of biologic agents and immunotherapies has led to recent improvements in disease-free and overall survival in select patient populations, and published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. This dynamic therapeutic environment requires the practicing oncology nurse to stay up to date on the benefits and risks of a plethora of novel and emerging treatment options.

    To bridge the gap between research and practice, this program features one-on-one interviews with 4 clinical investigators who participated in satellite symposia held in conjunction with the 2017 Oncology Nursing Society’s Annual Congress. These faculty members discuss recent clinical research findings in breast cancer (BC), ovarian cancer (OC), non-small cell lung cancer (NSCLC) and lymphomas and chronic lymphocytic leukemia (CLL). Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with these cancers.

    To present the most current research developments and to provide the perspectives of clinical investigators on the diagnosis and treatment of BC, OC, NSCLC and lymphomas and CLL.


    • Develop evidence-based strategies for the initial and long-term management of NSCLC, OC, BC, lymphomas and CLL.
    • Use an understanding of tumor biomarkers, histology and targetable genetic alterations to individualize the care of patients with NSCLC, OC, BC, lymphomas and CLL.
    • Refine or validate cancer-specific treatment algorithms based on existing and emerging research data.
    • Evaluate the mechanisms of action, tolerability and efficacy of novel agents under investigation in these tumor types, and consider their potential implications for clinical practice.
    • Recognize immune-related adverse events and other common side effects associated with approved and investigational immunotherapies in order to offer supportive management strategies.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


    This educational activity for 2.75 contact hours is provided by Research To Practice during the period of December 2017 through December 2018.

    This activity is awarded 2.75 ANCC pharmacotherapeutic contact hours.

    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/OncologyGrandRounds117/ILNA. ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

    This is an audio CNE program. This booklet contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/OncologyGrandRounds117 also includes links to relevant abstracts and full-text articles. To receive credit, participants should read the learning objectives and faculty disclosures, listen to the audio tracks and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/OncologyGrandRounds117/CNE. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 80% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SecordAdvisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Janssen Biotech Inc, Tesaro Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Eisai Inc, Endocyte Inc, Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Merck, Morphotek Inc, Tesaro Inc. Dr LaCasceAdvisory Committee: Forty Seven Inc. Dr YardleyAdvisory Committee: Novartis; Speakers Bureau: Eisai Inc, Genentech BioOncology. Dr JohnsonConsulting Agreements: Astellas Pharma Global Development Inc, Otsuka Pharmaceutical Co Ltd.

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Genentech BioOncology, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Seattle Genetics, Takeda Oncology and Tesaro Inc.

    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2017
    Expiration date: December 2018

Acknowledge and close

Listen to audio:
Oncology Grand Rounds: Investigators Discuss New Agents and Novel Therapies
Released December 2017

A special audio supplement to a CNE symposia series held during the 2017 ONS Annual Congress featuring expert comments on the application of emerging research to patient care. (Audio Content)

Read print: